{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"5"}],"title":">=3 line decrease"},{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"6"}],"title":">=2 but < 3 line decrease"},{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"10"}],"title":">=1 but < 2 line decrease"},{"measurements":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"41"}],"title":"<1 line decrease or any increase"}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"title":"Left Eye"},{"categories":[{"measurements":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"5"}],"title":">=3 line decrease"},{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"4"}],"title":">=2 but < 3 line decrease"},{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"8"}],"title":">=1 but < 2 line decrease"},{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"45"}],"title":"<1 line decrease or any increase"}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"title":"Right Eye"},{"categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"7"}],"title":">=3 line decrease"},{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"7"}],"title":">=2 but < 3 line decrease"},{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"15"}],"title":">=1 but < 2 line decrease"},{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"33"}],"title":"<1 line decrease or any increase"}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"title":"Worst Eye"}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"BCVA score was assessed individually for each eye. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any worst-case change from baseline categories are presented for right and left eyes. BCVA test scores were categorized as no change/improved vision, possible worsened vision and definite worsened vision. No change/improved vision was defined as a change from baseline \\<0.12 logMAR score; a possible worsened vision was defined as a change from baseline \\>=0.12 to \\<0.3 logMAR score; a definite worsened vision was defined as a change from baseline \\>=0.3 logMAR score. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle","id":"OG000","title":"Belantamab Mafodotin"},{"description":"Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \\>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)","id":"OG001","title":"Pomalidomide Plus Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified categories.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 263 weeks","title":"Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores","type":"SECONDARY","unitOfMeasure":"Participants"}